Multigene signatures for early breast cancer in clinical practice: A report of the Lombardy genomic assays for breast cancer working group

Multigene signatures for early breast cancer in clinical practice: A report of the Lombardy genomic assays for breast cancer working group

The increasing understanding of breast cancer biology has provided the basis for the development of multigene signatures aimed to improve the capability of clinicians to assess patients’ prognostication and risk stratification. Incorporating these tools in clinical practice has profoundly impacted o...

Full description

Bibliographic Details
Main Authors:	Luca Licata, Deborah Cosentini, Rita De Sanctis, Monica Iorfida, Elena Rota Caremoli, Andrea Vingiani, Edda Lucia Simoncini, Giancarlo Pruneri, Elisabetta Munzone, Giampaolo Bianchini, Alberto Zambelli, Carlo Tondini
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-03-01
Series:	Frontiers in Oncology
Subjects:	genomic test ER+/HER2- breast cancer early breast cancer adjuvant therapy multigene signatures
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1081885/full

Similar Items

Hormone Receptor Loss in Breast Cancer: Molecular Mechanisms, Clinical Settings, and Therapeutic Implications
by: Emma Zattarin, et al.
Published: (2020-12-01)

Prospective observational study on the impact of the 21-gene assay on treatment decisions and resources optimization in breast cancer patients in Lombardy: The BONDX study
by: Alberto Zambelli, et al.
Published: (2020-08-01)

The Role of Multigene Assays Adjuvant Treatment Decision for Early-Stage Breast Cancer
by: Cornelia NITIPIR, et al.
Published: (2020-06-01)

Moving HER2-low breast cancer predictive and prognostic data from clinical trials into the real world
by: Serena Di Cosimo, et al.
Published: (2022-09-01)

Biomarker and multigene assay testing in ER positive, HER-2 negative breast carcinomas: An international guidelines-based approach
by: Bradley M. Turner, et al.
Published: (2021-11-01)

Tissue- and liquid biopsy-based biomarkers for immunotherapy in breast cancer
by: Luca Licata, et al.
Published: (2023-06-01)

Should a Multigene Signature be Used in all Luminal Early Breast Cancers
by: Nawale Hajjaji, et al.
Published: (2019-06-01)

Clinical Utility of Multigene Profiling Assays in Early-Stage Invasive Breast Cancer: An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline
by: Phillip Blanchette, et al.
Published: (2022-04-01)

Differentiating HER2-low and HER2-zero tumors with 21-gene multigene assay in 2,295 HR + HER2- breast cancer: a retrospective analysis
by: Yoonwon Kook, et al.
Published: (2024-11-01)

Levels of uPA and PAI-1 in breast cancer and its correlation to Ki67-index and results of a 21-multigene-array
by: Hans-Ullrich Völker, et al.
Published: (2018-08-01)

Characterization of genetic predisposition to molecular subtypes of breast cancer in Brazilian patients
by: Daniele Paixão, et al.
Published: (2022-08-01)

The Role of Female Reproductive Hormones in the Association between Migraine and Breast Cancer: An Unanswered Question
by: Paola Tiberio, et al.
Published: (2023-06-01)

From seaside to bedside: Current evidence and future perspectives in the treatment of breast cancer using marine compounds
by: Rita De Sanctis, et al.
Published: (2022-09-01)

Assessment of <i>ERBB2</i> and HER2 expression in metastatic breast cancer using the nCounter® system and a 100-gene scale
by: R. M. Paltuev, et al.
Published: (2023-10-01)

BREAST CANCER TYPING USING RT-PCR ASSAY
by: V. K. Bozhenko, et al.
Published: (2019-11-01)

Management of Trastuzumab Deruxtecan-related nausea and vomiting in real-world practice
by: Giulia Notini, et al.
Published: (2024-03-01)

Multigene expression signatures in early hormone receptor positive HER 2 negative breast cancer
by: Ovcaricek Tanja, et al.
Published: (2019-09-01)

Clinical Review on the Management of Breast Cancer Visceral Crisis
by: Chiara Benvenuti, et al.
Published: (2023-04-01)

Guideline-Based, Multi-Gene Panel Germline Genetic Testing for at-Risk Patients with Breast Cancer
by: Abdel-Razeq H, et al.
Published: (2023-01-01)

Decentral gene expression analysis: analytical validation of the Endopredict genomic multianalyte breast cancer prognosis test
by: Kronenwett Ralf, et al.
Published: (2012-10-01)

Can multigene assays widen their clinical usefulness in early breast cancer treatment choice during the current COVID-19 outbreak in Italy?
by: Alberto Zambelli, et al.
Published: (2020-11-01)

Association between 15 known or potential breast cancer susceptibility genes and breast cancer risks in Chinese women
by: Fenfen Fu, et al.
Published: (2022-02-01)

Germline mutation landscape of Chinese patients with familial breast/ovarian cancer in a panel of 22 susceptibility genes
by: Jiayu Wang, et al.
Published: (2019-05-01)

Management of BRCA Tumour Testing in an Integrated Molecular Tumour Board Multidisciplinary Model
by: Jacopo Azzollini, et al.
Published: (2022-04-01)

Male Breast Cancer: Results of the Application of Multigene Panel Testing to an Italian Cohort of Patients
by: Gianluca Tedaldi, et al.
Published: (2020-04-01)

Polymorphism of hormone synthesis and metabolizing genes and breast cancer risk: A multigenic case-control study
by: Anurupa Chakraborty, et al.
Published: (2016-01-01)

Cost-Effectiveness Analysis of the Oncotype DX Breast Recurrence Score® Test in Node-Negative Early Breast Cancer
by: Berdunov V, et al.
Published: (2022-09-01)

Somatic Mutations Alter Interleukin Signaling Pathways in Grade II Invasive Breast Cancer Patients: An Egyptian Experience
by: Auhood Nassar, et al.
Published: (2022-11-01)

Implementation of multigene panel testing for breast and ovarian cancer in South Africa: A step towards excellence in oncology for the public sector
by: Nerina C. van der Merwe, et al.
Published: (2022-12-01)

A portrait of germline pathogenic variants in high and moderate penetrance breast cancer genes in Brazil
by: Leandro Jonata de Carvalho Oliveira, et al.
Published: (2024-12-01)

Fulvestrant in Combination with CDK4/6 Inhibitors for HER2- Metastatic Breast Cancers: Current Perspectives
by: Iorfida M, et al.
Published: (2020-03-01)

Charting the Course in Sequencing Antibody-Drug Conjugates in Breast Cancer
by: Giuseppe Saltalamacchia, et al.
Published: (2024-02-01)

Hormone receptor status influences the impact of body mass index and hyperglycemia on the risk of tumor relapse in early-stage HER2-positive breast cancer patients
by: Francesca Ligorio, et al.
Published: (2021-04-01)

Multi-gene panel testing increases germline predisposing mutations’ detection in a cohort of breast/ovarian cancer patients from Southern Italy
by: Marcella Nunziato, et al.
Published: (2022-08-01)

Variants of cancer susceptibility genes in Korean BRCA1/2 mutation-negative patients with high risk for hereditary breast cancer
by: Ji Soo Park, et al.
Published: (2018-01-01)

Alternaria brown spot on new clones of sweet orange and lemon in Italy
by: Dalia AIELLO, et al.
Published: (2020-03-01)

Breast cancer /
by: Barber, Matthew D. 534305, et al.
Published: (2012)

HR+/HER2– de novo metastatic breast cancer: a true peculiar entity?
by: Rosalba Torrisi, et al.
Published: (2023-03-01)

A cost-consequence analysis of adding pertuzumab to the neoadjuvant combination therapy in HER2-positive high-risk early breast cancer in Italy
by: Alberto Zambelli, et al.
Published: (2023-10-01)

MRI-Derived Tumour-to-Breast Volume Is Associated with the Extent of Breast Surgery
by: Andrea Cozzi, et al.
Published: (2021-01-01)